Diamyd Medical AB (publ)
SSE:DMYD-B.ST
13.3 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Diamyd Medical AB (publ) |
Symbool | DMYD-B.ST |
Munteenheid | SEK |
Prijs | 13.3 |
Beurswaarde | 1,226,345,120 |
Dividendpercentage | 0% |
52-weken bereik | 6.41 - 20.992 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Ulf Hannelius MBA, Ph.D. |
Website | https://www.diamyd.com |
An error occurred while fetching data.
Over Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)